{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2"},{"groupId":"OG001","value":"98.3"},{"groupId":"OG002","value":"95.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"43"}],"units":"Participants"}],"description":"Concomitant medications were medications that were ongoing or initiated after the first dose of the study drug but before the last dose plus 28 days. Percentage of participants who required at least one concomitant medications during the study along with their prescribed study drug (AG-120 or placebo) were reported.","groups":[{"description":"Participants received AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study for up to approximately 45 months.","id":"OG000","title":"AG-120"},{"description":"Participants received AG-120 matched placebo, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up or the sponsor ended the study for up to approximately 7 months. Participants who experienced disease progression and received placebo were allowed to cross over and receive AG-120.","id":"OG001","title":"Placebo"},{"description":"Participants who experienced disease progression and received placebo were allowed to cross over to receive AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle for up to approximately 32 months.","id":"OG002","title":"After Crossover to AG-120"}],"paramType":"NUMBER","populationDescription":"SAS included all participants who received at least one dose of study drug (AG-120 or Placebo).","reportingStatus":"POSTED","timeFrame":"From first dose of study drug up to 28 days after last dose (Up to approximately 4 Years)","title":"Percentage of Participants Who Required At Least One Concomitant Medications During the Treatment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}